The goal of this clinical trial is to evaluate the safety and find the optimal dose of the investigational drug Iberdomide by itself and in combinations with other approved treatments.
SparkCures ID | 865 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 449 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors